# Ingenium Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ingenium-pharmaceuticals

- Industry: Biotechnology
- Headquarters: Germany
- Website: www.ingenium-ag.com
- Total disclosed funding: $29M
- Latest round: Series D (Apr 1, 2006)
- Investors on record: 8

## About

Ingenium Pharmaceuticals AG specializes in biotechnology, focusing on the development and production of innovative biotechnological products aimed at enhancing medical diagnostics and scientific research.Ingenium Pharmaceuticals AG, based in Germany, operates in the biotechnology sector by developing advanced solutions for medical diagnostics. Founded in 1998, the company has undergone several operational strategies, including its acquisition by Helmholtz Zentrum in June 2008 for an undisclosed amount. The current CEOs are Heike Lührs and Norman Boss. Since its inception, the company has successfully secured funding through various rounds, culminating in a Series D funding round in which it raised EUR 9.20 mn from investors including HBM Partners and TVM Capital Life Science. Overall, Ingenium has completed four funding deals, with the last one occurring in 2008.Ingenium Biologicals Biotech (IBB) specializes in creating advanced biotechnological products, primarily focused on enzyme-linked immunosorbent assay (ELISA) kits, next-generation antibodies, and glycosylation research tools. These products are essential for medical diagnostics and scientific research, addressing crucial healthcare requirements including disease detection, vaccine development, and therapeutic advancements. IBB serves a variety of clients, from pharmaceutical companies to research institutions and diagnostic laboratories across North America, Europe, and Asia-Pacific, providing necessary tools for innovative research and development.In the most recent year, Ingenium Biologicals Biotech reported a revenue of EUR 951,854.10, reflecting its business-to-business model focused on sales to research institutions and pharmaceutical partnerships. The company’s revenue generation primarily relies on bulk orders of its ELISA kits and antibody products, with tailored pricing plans based on clients’ needs. Despite reporting an EBITDA loss of EUR 6,148,751.60, Ingenium continues to cater to high-demand sectors in medical diagnostics and research, supported by its global market presence.Ingenium Pharmaceuticals AG is focused on expanding its product line, with plans to introduce new advanced biotechnological products to the market following the latest funding round. The strategic use of the EUR 9.20 mn raised during the Series D round is directed toward product development and enhancing market reach. The company aims to penetrate additional geographic markets, specifically targeting North America and Asia-Pacific, by 2025. This expansion strategy aligns with Ingenium's objective to strengthen its position in the biotechnology sector following its acquisition in 2008.

## Funding rounds

- Series D, Apr 1, 2006, $11M — TVM Capital Life Science, HBM Partners
- Series C, Dec 1, 2003, $17M — Index Ventures, Sofinnova Partners, TVM Capital Life Science, Polaris Partners, HBM Partners, IKB Invest, SV Health Investors, Ascenion GmbH

## Investors

- Index Ventures (https://capitalatlas.ai/funds/index-ventures) — Series C
- Sofinnova Partners (https://capitalatlas.ai/funds/sofinnova-partners) — Series C
- TVM Capital Life Science (https://capitalatlas.ai/funds/tvm-capital-life-science) — Series C, Series D
- Polaris Partners (https://capitalatlas.ai/funds/polaris-partners) — Series C
- HBM Partners (https://capitalatlas.ai/funds/hbm-partners) — Series C, Series D
- IKB Invest (https://capitalatlas.ai/funds/ikb-invest) — Series C
- SV Health Investors (https://capitalatlas.ai/funds/sv-health-investors) — Series C
- Ascenion GmbH — Series C